Charles Roco
Charles Roco is currently Co-Founder and CTO at Parse Biosciences, a startup that was acquired. He previously held research roles at Harvard School of Engineering and Applied Sciences, MITRE, University of Pennsylvania, and University of Washington Bioengineering, and worked in engineering at the US Department of Transportation.
Seattle’s UW research, Amazon alumni and military adjacency fuel startups building high-stakes, regulation-ready AI for biotech, finance and government
A Seattle high-school intern argues that strict school AI rules illuminated why AI must be disciplined in high-stakes domains, and describes how Seattle's research institutions (notably UW and the David Baker ecosystem), Amazon alumni, and military adjacency produce founders building accountable, regulation-ready AI for biotech, finance, and government.
Qiagen to Acquire Seattle’s Parse Biosciences for $225 Million in Cash Deal Closing December 2023
Seattle's Parse Biosciences, a single-cell RNA sequencing company founded in 2018, is being acquired by Netherlands-based Qiagen in a $225 million cash deal expected to close in December. Parse, which serves 3,000 customers globally and raised over $50 million in funding, will continue operating from its Seattle headquarters as a Qiagen subsidiary.
Five Finalists for 2022 GeekWire Health Innovation of the Year Include A-Alpha Bio and UW Institute for Protein Design
The 2022 GeekWire Health Innovation of the Year finalists include A-Alpha Bio, Parse Biosciences, Tasso, Truveta, and the University of Washington’s Institute for Protein Design, highlighting advances in computational health approaches. Winners will be announced on May 12 at the GeekWire Awards, with community voting open until April 22.
Parse Biosciences raises $41.5M to scale Evercode single-cell RNA sequencing kits that profile up to 1M cells
Parse Biosciences, a Seattle startup co-founded by CEO Alex Rosenberg and CTO Charles Roco, raised $41.5 million to expand its single-cell RNA sequencing kits and software, which scale to profile up to one million cells using standard lab equipment. The company, launched from University of Washington research, now has more than 300 customers and emphasizes ease of use versus competitors requiring specialized hardware.
Parse Biosciences raises $7M led by Bioeconomy Capital to scale single-cell RNA-seq tech; total funding $9M
Parse Biosciences (formerly Split Biosciences) raised $7 million to grow its single-cell RNA-seq 'Whole Transcriptome Kit' that profiles up to 100,000 cells across 48 samples; the 16-person startup spun out of UW in 2018 and has 40+ labs using its kit.
Organizations
See all 9-
Parse Biosciences Co-Founder and CTO 2018–present · current
-
Split Biosciences Executive Officer, Director, Promoter 2018 · past
-
University of Washington Bioengineering Graduate Research Assistant 2015–2019 · past
Education
-
University of Washington Doctor of Philosophy - PhD, Bioengineering · 2015–2019
-
Virginia Tech Bachelor of Science (B.S.), Biological Systems Engineering · 2011–2015
